Med. praxi. 2024;21(3):170-176

Obezita a farmakoterapie pod lupou

MUDr. Zuzana Zafarová

Zpracováno na základě přednášek doc. MUDr. Ľubici Cibičkové, Ph.D., a doc. MUDr. Martina Anderse, Ph.D.

Published: June 17, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zafarová Z. Obezita a farmakoterapie pod lupou. Med. praxi. 2024;21(3):170-176.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014 Jun; 84:1-11. Go to original source... Go to PubMed...
    2. Yu JH, Kim MS. Molecular mechanisms of appetite regulation. Diabetes Metab J. 2012 Dec;36(6):391-398. Go to original source... Go to PubMed...
    3. Morton GJ, Cummings DE, Baskin DG, et al. Central nervous system control of food intake and body weight. Nature. 2006 Sep 21;443(7109):289-295. Go to original source... Go to PubMed...
    4. Volkow ND, Wang GJ, Tomasi D, Baler RD. Obesity and addiction: neurobiological overlaps. Obes Rev. 2013 Jan;14(1):2-18. Go to original source... Go to PubMed...
    5. Aparicio E, Canals J, Arija V, et al. The role of emotion regulation in childhood obesity: implications for prevention and treatment. Nutr Res Rev. 2016 Jun;29(1):17-29. Go to original source... Go to PubMed...
    6. Schulte EM, Avena NM, Gearhardt AN. Which foods may be addictive? The roles of processing, fat content, and glycemic load. PLoS One. 2015 Feb 18;10(2):e0117959. Go to original source... Go to PubMed...
    7. Dalton M, Finlayson G, Walsh B, et al. Early improvement in food cravings are associated with long­‑term weight loss success in a large clinical sample. Int J Obes (Lond). 2017 Aug;41(8):1232-1236. Go to original source... Go to PubMed...
    8. Acosta A, Camilleri M, Abu Dayyeh B, et al. Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic. Obesity (Silver Spring). 2021 Apr;29(4):662-671. Go to original source... Go to PubMed...
    9. Glider K, Dalto, M, Halseth A, et al. PP5.13 Food craving and weight loss: An integrated analysis of the effects of prolonged release naltrexone/bupropion on the cravings and mood sub­‑scales of the Control of Eating Questionnaire. Obesity Facts. 2016;9(suppl 1):80-80.
    10. SPC Mysimba. www.sukl.cz
    11. Walsh B, Plodkowski RA, Shan K, et al. T8:PO.108 Early achievement of significant weight loss with prolonged release naltrexone/bupropion is associated with additional weight loss at one year - an integrated analysis of four phase 3 trials. Obesity Facts. 2015;8(suppl 1):240-240.
    12. Clayton P, Rowbotham J. How the mid­‑Victorians worked, ate and died. Int J Environ Res Public Health. 2009 Mar;6(3):1235-1253. Go to original source... Go to PubMed...
    13. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med. 2002 Sep 19;347(12):911-920. Go to original source... Go to PubMed...
    14. Davidson TL, Tracy AL, Schier LA, et al. A view of obesity as a learning and memory disorder. J Exp Psychol Anim Learn Cogn. 2014 Jul;40(3):261-279. Go to original source... Go to PubMed...
    15. Egger G, Dixon J. Beyond obesity and lifestyle: a review of 21st century chronic disease determinants. Biomed Res Int. 2014;2014:731685. Go to original source... Go to PubMed...
    16. Antza C, Kostopoulos G, Mostafa S, et al. The links between sleep duration, obesity and type 2 diabetes mellitus. J Endocrinol. 2021 Dec 13;252(2):125-141. Go to original source... Go to PubMed...
    17. Karczewski J, Zielińska A, Staszewski R, et al. Obesity and the Brain. Int J Mol Sci. 2022 May 30;23(11):6145. Go to original source... Go to PubMed...
    18. Woo A, Botta A, Shi SSW, et al. Obesity­‑Related Neuroinflammation: Magnetic Resonance and Microscopy Imaging of the Brain. Int J Mol Sci. 2022 Aug 8; 23(15): 8790. Go to original source... Go to PubMed...
    19. Anders M, Gkalpakiotis S, Rob F, et al. Atopická dermatitida a psychické komorbidity. Čes­‑slov Derm. 2022;97(5):196-208.
    20. Ryan SM, Nolan YM. Neuroinflammation negatively affects adult hippocampal neurogenesis and cognition: can exercise compensate? Neurosci Biobehav Rev. 2016 Feb;61:121-31. Go to original source... Go to PubMed...
    21. Halaris A, Leonard BE (eds). Neuroprogression in Psychiatric Disorders. Basel, Karger. 2017:182 s. Go to original source...
    22. Haroon E, Miller AH, Sanacora G. Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders. Neuropsychopharmacology. 2017 Jan;42(1):193-215. Go to original source... Go to PubMed...
    23. Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014 Jun;84:1-11. Go to original source... Go to PubMed...
    24. Tafseer S, Gupta R, Ahmad R, et al. Bupropion monotherapy alters neurotrophic and inflammatory markers in patients of major depressive disorder. Pharmacol Biochem Behav. 2021 Jan;200:173073. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.